Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Immunon Inc (IMNN) is a clinical-stage biotechnology pioneer developing DNA-based immunotherapies through its proprietary non-viral platform. This page serves as the definitive source for verified company updates, including clinical trial progress, regulatory milestones, and research breakthroughs.
Investors and researchers will find timely updates on key programs like the IMNN-001 ovarian cancer therapy (Phase II completed) and IMNN-101 COVID-19 booster candidate. Our curated news feed covers essential developments including partnership announcements, intellectual property updates, and peer-reviewed study publications.
Content is organized to highlight material events across three core areas: Clinical Trial Advancements, Regulatory Pathway Updates, and Technology Platform Innovations. Each update is vetted for relevance to stakeholders monitoring the company's progress in immuno-oncology and infectious disease applications.
Bookmark this page for structured access to Immunon's official communications, including SEC filings analysis and conference presentation summaries. Check regularly for developments in DNA-based therapeutic approaches that aim to redefine cancer treatment and vaccine development paradigms.
IMUNON, Inc. (NASDAQ: IMNN) announces the activation of the first site for its Phase 1 study with IMNN-101, a seasonal Covid-19 vaccine, utilizing its proprietary PlaCCine platform. The study aims to evaluate safety, tolerability, and immune response in healthy adults. Topline results are expected by year-end. IMNN-101 is designed to protect against the SARS-CoV-2 Omicron XBB1.5 variant, with potential advantages over mRNA vaccines in terms of immune protection and vaccine stability.
IMUNON, Inc. (NASDAQ: IMNN) reported financial results for Q1 2024, highlighting clinical development programs with promising results for IMNN-001 immunotherapy and PlaCCine modality. The company also appointed Dr. Stacy Lindborg as President and CEO. Recent developments include positive data in advanced ovarian cancer studies and progress in developing a seasonal COVID-19 booster vaccine. IMUNON received non-dilutive funding and reported a net loss of $4.9 million for Q1 2024.
IMUNON, Inc. (NASDAQ: IMNN) appointed Dr. Stacy R. Lindborg as President and CEO, bringing extensive experience in drug development. Dr. Lindborg takes over at a critical time with key clinical milestones approaching. IMNN-001 results in advanced ovarian cancer expected mid-summer, while Phase 1 data for IMNN-101 in seasonal COVID-19 are anticipated by year-end.
IMUNON, Inc. (NASDAQ: IMNN) will host a conference call on May 13, 2024, to discuss financial results for the first quarter of 2024. The company will provide updates on its clinical development programs, including IMNN-001 for ovarian cancer treatment and the PlaCCine modality for next-generation vaccines.
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
